Work

Abstract 4353: A phase I open-label positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-4353

Authors: Kowser Miah, Zsolt Cselényi, Jonas Svensson, Aurelija Jucaite, Ike Igwegbe, Caitlin Muldoon, Miriam Zanuy Porquet, Kenneth Dahl, Peter Johnström, Miguel A. Cortés González, Antonia Högnäsbacka, Andrea Varrone, Karthick Vishwanathan, Magnus Schou

Institutions: AstraZeneca (United States), AstraZeneca (Sweden), Region Stockholm, Karolinska Institutet, AstraZeneca (United Kingdom), AstraZeneca (Spain)

Language: English

Topic: Barrier Structure and Function Studies

Subfield: Neurology

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409636127

Cites:

Cited by: 1

Related to: 10